New anti-evolocumab antibodies could aid drug development
Drug Discovery World
SEPTEMBER 1, 2022
Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .
52 
Let's personalize your content